original articlesphase I and pharmacolineticsPhase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
phase I and pharmacolinetics
Under an Elsevier user license
open archive
Keywords
apoptosis
HGS-ETR2
lexatumumab
pharmacokinetics
phase I
TRAIL-R2
Cited by (0)
- †
Present address: Department of Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio, TX, USA.
Copyright © 2009 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.